TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14731162

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (ritonavir or indinavir)
Number of subjects: 1251

Group type: COMPARATOR
Intervention: HAART regimen
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Zidovudine and zalcitabine in the prescribed regimen
Number of subjects: 1251
Study: 11348957

Group type: EXPERIMENTAL
Intervention: IV theophylline
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no theophylline)
Number of subjects: 47
Study: 9292946

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 62

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 62
Study: 8413073

Group type: EXPERIMENTAL
Intervention: Data-based medical practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 3812184

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single-rate ventricular pacing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both pacing modes (ventricular and dual-chamber)
Number of subjects: 14
Study: 28547269

Group type: EXPERIMENTAL
Intervention: Continuous bladder catheterization (CC)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Intermittent bladder catheterization (IC)
Number of subjects: 184
Study: 26699599

Group type: EXPERIMENTAL
Intervention: CABG with acute kidney injury (AKI)
Number of subjects: 1406

Group type: COMPARATOR
Intervention: CABG without acute kidney injury (AKI)
Number of subjects: 1406
Study: 24206528

Group type: EXPERIMENTAL
Intervention: Endovascular hypothermia combined with thrombolysis
Number of subjects: 400

Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 400
Study: 22198532

Group type: EXPERIMENTAL
Intervention: Right hand training with 30° clockwise cursor rotation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left hand training with 30° clockwise cursor rotation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20167144

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 1 (96 actuations, 24 days)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 2 (120 actuations, 30 days)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI with actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Group 3 (128 actuations, 32 days)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Budesonide/formoterol pMDI without actuation counter (80/4.5 micrograms x 2 inhalations [160/9 micrograms] twice daily) - Run-in period
Number of subjects: 254
Study: 18062023

Group type: EXPERIMENTAL
Intervention: Combined electric, electromagnetic, quantum and microvibration therapy with basic treatment (antiaggregants, beta-blockers, statins)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Laser therapy with basic treatment (antiaggregants, beta-blockers, statins)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Basic treatment without physiotherapy
Number of subjects: 150
Study: 16236892

Group type: EXPERIMENTAL
Intervention: Meropenem/tobramycin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ceftazidime/tobramycin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Open-label meropenem/tobramycin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups (meropenem/tobramycin, ceftazidime/tobramycin, open-label meropenem/tobramycin)
Number of subjects: 102
Study: 12134936

Group type: EXPERIMENTAL
Intervention: 0.5 ml of 1% lidocaine injected into the carotid sinus nerve
Number of subjects: 92

Group type: COMPARATOR
Intervention: No injection of lidocaine
Number of subjects: 92
Study: 10195549

Group type: COMPARATOR
Intervention: 2.5 mg/kg propofol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% sevoflurane
Number of subjects: 20
Study: 7540039

Group type: EXPERIMENTAL
Intervention: PVB/BEP
Number of subjects: 234

Group type: COMPARATOR
Intervention: BEP
Number of subjects: 234
Study: 1332625

Group type: EXPERIMENTAL
Intervention: NK-121
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DWA-2114R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 254-S
Number of subjects: 0

Group type: COMPARATOR
Intervention: 254-S plus VDS
Number of subjects: 0

Group type: COMPARATOR
Intervention: CDDP plus VDS
Number of subjects: 0
Study: 4061377

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg I.V. before therapy, and 4 mg I.V. q 4 h X 6 doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30045185

Group type: EXPERIMENTAL
Intervention: EXC 001 (5 mg/cm)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 25852193

Group type: EXPERIMENTAL
Intervention: Adaptive Statistical Iterative Reconstruction (ASIR) protocol (n=64)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard Filtered Back Projection (FBP) protocol (n=58)
Number of subjects: 122
Study: 26214544

Group type: EXPERIMENTAL
Intervention: MI‐PC (motivational-interviewing with patient choice)
Number of subjects: 500

Group type: COMPARATOR
Intervention: MI‐IOP (motivational-interviewing focused on engagement in an IOP)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No further outreach
Number of subjects: 500
Study: 23509000

Group type: EXPERIMENTAL
Intervention: Plastic model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Static computer-based module (Key Views)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Virtual reality computer-based module
Number of subjects: 60
Study: 20870113

Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 15.0 mg/mL (1.5%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 30.0 mg/mL (3.0%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 0.15 to 5.00 mg/mL (0.015% to 0.500%)
Number of subjects: 42
Study: 18812761

Group type: EXPERIMENTAL
Intervention: McCarey-Kaufman (MK) medium
Number of subjects: 18

Group type: COMPARATOR
Intervention: Organ culture (OC)
Number of subjects: 18
Study: 16615926

Group type: EXPERIMENTAL
Intervention: High-dose magnesium sulfate (50 mg/kg load and 2 g/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose magnesium sulfate (25 mg/kg load and 1 g/h)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose magnesium sulfate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose magnesium sulfate
Number of subjects: 120
Study: 12791810

Group type: EXPERIMENTAL
Intervention: (18)F‐FECNT PET scanning in healthy subjects
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: (18)F‐FECNT PET scanning in early-stage unilateral PD patients
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: (18)F‐FECNT PET scanning in late-stage PD patients
Number of subjects: 11
Study: 11009288

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 7626347

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 2199622

Group type: EXPERIMENTAL
Intervention: Fluorouracil, doxorubicin (Adriamycin), and mitomycin (FAM)
Number of subjects: 281

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 281
Study: 229707

Group type: EXPERIMENTAL
Intervention: FOY injectable
Number of subjects: 201

Group type: COMPARATOR
Intervention: Trasylol
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: FOY-305 oral capsule
Number of subjects: 201

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 201
Study: 31343948

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) supplementation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chronic BJ supplementation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chronic nitrate-depleted beetroot juice (NDBJ) supplementation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: BJ and NDBJ supplementation
Number of subjects: 23
Study: 28647340

Group type: EXPERIMENTAL
Intervention: Patient specific training using 3D printed aneurysms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (routine procedure without simulator training)
Number of subjects: 10
Study: 25752903

Group type: EXPERIMENTAL
Intervention: Group BII: Initial bolus plus early start of the intermittent infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Group DII: No bolus plus delayed start (8 h) of the intermittent infusion
Number of subjects: 18
Study: 23635846

Group type: EXPERIMENTAL
Intervention: CBTp (Cognitive Behavioural Therapy) + TAU (Treatment as Usual)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waiting-list group (Control)
Number of subjects: 45
Study: 21503861

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC) model
Number of subjects: 481

Group type: COMPARATOR
Intervention: Conventional Care (CG)
Number of subjects: 481
Study: 17879970

Group type: EXPERIMENTAL
Intervention: Basic communication skills training program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication skills training program with consolidation workshops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physicians' communication skills (breaking bad news)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-reported distress by patients and relatives
Number of subjects: 0
Study: 16490974

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Iodine-free product
Number of subjects: 5
Study: 14499051

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study: 10718501

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 39876

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo (for aspirin)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo (for vitamin E)
Number of subjects: 39876
Study: 9197297

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine 1% (30 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2-chloroprocaine 3% (10 ml)
Number of subjects: 12
Study: 7507933

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypnosis with Lorazepam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3569828

Group type: COMPARATOR
Intervention: 3 ml 5% tylose
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 micrograms sulprostone gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 micrograms sulprostone gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 ml 2.5 mM calcium chloride gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 ml 9.0 mM calcium chloride gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sulprostone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: calcium chloride gel
Number of subjects: 50
Study: 29627621

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (flexible take-home doses)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Methadone (daily witnessed ingestion)
Number of subjects: 276
Study: 26707685

Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 25343191

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio (WHtR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 90
Study: 22971323

Group type: EXPERIMENTAL
Intervention: Empiric albendazole every 3 months plus praziquantel annually
Number of subjects: 948

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Empiric albendazole plus praziquantel
Number of subjects: 948
Study: 20795922

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Progressive resistance exercise and Aerobic exercise)
Number of subjects: 60
Study: 18948442

Group type: EXPERIMENTAL
Intervention: Specific strength training of the neck/shoulder muscles
Number of subjects: 42

Group type: COMPARATOR
Intervention: General fitness training performed as leg bicycling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference intervention without physical activity
Number of subjects: 42
Study: 16167129

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 0
Study: 12699023

Group type: EXPERIMENTAL
Intervention: Behavior therapy and nicotine patch
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Postcessation self-efficacy
Number of subjects: 121
Study: 10226092

Group type: EXPERIMENTAL
Intervention: Beta-blockers and amiodarone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Beta-blockers alone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Neither beta-blockers nor amiodarone
Number of subjects: 4
Study: 8688255

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 6 ml h‐1
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 8 ml h‐1
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 10 ml h‐1
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 12 ml h‐1
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine at 14 ml h‐1
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no postoperative extradural infusion)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All ropivacaine infusion groups
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All groups (end of study)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Higher ropivacaine infusion rates
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Higher rates of ropivacaine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 151
Study: 1676364

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 0
Study: 6219403

Group type: EXPERIMENTAL
Intervention: Abdominal muscle strength training (12-session training program)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study: 30047838

Group type: EXPERIMENTAL
Intervention: Low social power state
Number of subjects: 0

Group type: COMPARATOR
Intervention: High social power state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral social power state
Number of subjects: 0
Study: 30096639

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27706777

Group type: EXPERIMENTAL
Intervention: New SSR markers developed for Capsicum, specifically 144 SSR markers tested on cultivated and wild species.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cross-species transferability of 91 SSR markers tested on seven cultivated and wild Capsicum species.
Number of subjects: 48
Study: 25262145

Group type: EXPERIMENTAL
Intervention: Wahakura
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bassinet
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Wahakura and Bassinet
Number of subjects: 200
Study: 22098257

Group type: EXPERIMENTAL
Intervention: Housing and case management program
Number of subjects: 407

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study: 18774743

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (DA) as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (DA) as adjunctive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (DA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study: 17335818

Group type: COMPARATOR
Intervention: Metformin (1,500 mg/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: N‐acetyl cysteine (1.8 g/d)
Number of subjects: 61
Study: 15470328

Group type: EXPERIMENTAL
Intervention: 40 mg rabeprazole once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole 4 times daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11162336

Group type: EXPERIMENTAL
Intervention: Community action intervention
Number of subjects: 20
Study: 9678535

Group type: EXPERIMENTAL
Intervention: Small iodine supplements (Thyrojod depot tablets containing 1530 microg iodide) every 2 weeks for 2 years followed by once weekly for 2 years.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no iodine supplements).
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Small iodine supplements (Thyrojod depot tablets containing 1530 microg iodide).
Number of subjects: 117
Study: 8034818

Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD) - 420-kcal/day liquid diet for 16 weeks, then 1,200-kcal/day diet
Number of subjects: 49

Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD) - 1,200-kcal/day diet throughout treatment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD)
Number of subjects: 49
Study: 2648767

Group type: EXPERIMENTAL
Intervention: 200‐300 mg/day of trazodone
Number of subjects: 48

Group type: COMPARATOR
Intervention: 200‐300 mg/day trazodone plus 1 ampoule (1000 gamma of lipidic phosphorous) twice daily of hypothalamic phospholipids (HPL)
Number of subjects: 48
Study: 29696945

Group type: EXPERIMENTAL
Intervention: Chewing-gum (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 22
Study: 29847665

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with Dk/t range of 31 to 211 units
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (contralateral eye without lens)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 29
Study: 28542926

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25628173

Group type: EXPERIMENTAL
Intervention: Hi-HiLo (living high and training high and low for 4 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hi-Hi (living and training at moderate altitude for 3 and 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: SL (living and training at sea level for 4 weeks)
Number of subjects: 54
Study: 22390966

Group type: EXPERIMENTAL
Intervention: Disease targeting therapies (DTT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Escalation of therapy
Number of subjects: 79
Study: 21681698

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 37
Study: 19389004

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg on-demand 0.75-2 hours before sexual stimulation
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 16774799

Group type: EXPERIMENTAL
Intervention: Elemental oral nutrition supplements
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peptide oral nutrition supplements
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Polymeric oral nutrition supplements
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls (N=50)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 50
Study: 15319723

Group type: EXPERIMENTAL
Intervention: MISTELS simulator practice (transfer drill) for 4 weeks
Number of subjects: 215

Group type: COMPARATOR
Intervention: No practice of the transfer drill
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: MISTELS scores
Number of subjects: 215
Study: 11207404

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg intramuscularly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Meperidine 1.5 mg/kg (max 100 mg) intramuscularly
Number of subjects: 30
Study: 9278654

Group type: EXPERIMENTAL
Intervention: Aprotinin (loading dose of 2 x 10(6) KI units followed by 0.5 x 10(6) KI units/h)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 136
Study: 8472112

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Computed Tomography
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combined Ultrasound and Computed Tomography
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ultrasound and Computed Tomography
Number of subjects: 113
Study: 3725504

Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate for 24 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate for 16 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate of 4 g/kg for 24 hours
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Infusion rates as used in the study
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Infusion of fat at a constant rate for 24 hours
Number of subjects: 41
Study: 30462279

Group type: EXPERIMENTAL
Intervention: Continued DOAC (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Interrupted DOAC (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 662
Study: 26698676

Group type: EXPERIMENTAL
Intervention: Fertility medication (selective estrogen receptor modulator, gonadotropin, or other) or infertility treatment (IVF or IUI)
Number of subjects: 941
Study: 24584875

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard external beam radiation therapy (EBRT)
Number of subjects: 0
Study: 23235414

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 60